Counseling Patients and Caregivers on NSCLC Treatment Toxicities

Opinion
Video

The panelists explore the importance of communicating with patients, nurses, and caregivers about potential adverse reactions and injection site reactions, while emphasizing the need to offer ongoing reassurance and support throughout the treatment journey.

CN_TA_24_NSCLC_Seg03_Infusion
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
      Hospital Length of Stay After NSCLC Surgery Higher With Wildfire Exposure
      6 experts are featured in this series.
      Future Therapies for ALK+ Metastatic NSCLC
      6 experts are featured in this series.
      Evaluating ALK Inhibitors in Treatment Sequencing and Testing
      6 experts are featured in this series.
      Treatment Strategies in Disease Progression in ALK+ NSCLC
      6 experts are featured in this series.
      Patient Factors Considered when Choosing Treatment Selection
      6 experts are featured in this series.
      KRAS+ NSCLC: Treatment Management Strategies
      6 experts are featured in this series.
      Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?
      6 experts are featured in this series.
      KRAS G12 Inhibitor Treatment Options
      6 experts are featured in this series.
      Clinical Experience of Lorlatinib ALK+ NSCLC Patients
      6 experts are featured in this series.
      Overview of Current Treatment Landscape of ALK Inhibitors
      Related Content
      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

      Prioritizing Climate Hazard Preparedness Following NSCLC Surgery

      Russ Conroy
      March 28th 2025
      Article

      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Navigating Management and Dosing Considerations for Amivantamab in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      February 10th 2025
      Podcast

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

      Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

      Tim Cortese
      March 25th 2025
      Article

      In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.

      Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

      Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

      Terence T. Sio, MD, MS
      June 3rd 2024
      Podcast

      Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

      Wildfire Exposure Confers Longer Length of Stay Following NSCLC Surgery | Image Credit: © appledesign - stock.adobe.com.

      Wildfire Exposure Confers Longer Length of Stay Following NSCLC Surgery

      Russ Conroy
      March 20th 2025
      Article

      Future work may need to assess whether extended hospital stays improve surgical care outcomes during disasters, according to one of the study authors.

      Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

      Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases

      Russ Conroy
      March 12th 2025
      Article

      Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.